journal article·2019-12-04Open access

Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV

Davood Mansury, Kiarash Ghazvini, Saeid Amel Jamehdar, Ali Badiee, Mohsen Tafaghodi, Amin Reza Nikpoor, Yousef Amini, Mahmoud Reza Jaafari

Abstract

Tuberculosis has been a major health problem worldwide for years; therefore, it is important to develop and produce an effective vaccine against this disease. In this study, the immunogenicity of Mycobacterium tuberculosis fusion protein (FP) encapsulated in liposomes containing DDA/TDB was evaluated. The FP was expressed in E. coli BL21 and encapsulated in liposomal formulations. Three weeks after the last subcutaneous immunization, IFN-γ, IL-4, IL-17, and IL-12 in spleen cell culture supernatants, and IgG2a, IgG1, and IgG2b titres in sera were measured. The greatest IFN-γ and IL-12 interleukin concentrations were observed in the DDA/TDB/CHOL liposomes containing the FP. Initial injection with BCG improved the efficacy of the DDA/TDB/CHOL/FP vaccine. The IgG2a/IgG1 ratio was also high in the DDA/TDB/CHOL/FP group; furthermore, the IgG2a/IgG1 ratio was increased in the BCG-primed, DDA/TDB/CHOL/FP-boosted group, indicating induction of a cellular immune response. Our study showed that the FP-containing DDA/TDB/CHOL liposomes induced a Th1 response. However, the groups that first received BCG and then DDA/TDB/CHOL/FP had the greatest Th1 response in terms of IFN-γ and IL-12 production of all the groups. This suggests that these formulations enhance the BCG vaccine's effectiveness.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Tuberculosis Research and Epidemiology · Pneumocystis jirovecii pneumonia detection and treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences

Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences

Nanotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences

Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences

Department of Immunology, School of Medicine, Mashhad University of Medical Sciences

Department of Microbiology and Virology, School of Medicine, Zahedan University of Medical Sciences

Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences

Funding

Nanotechnology Research Center and Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences

References (57)

Show source-provided references
1. 10.1111/jphp.1239010.1111/jphp.12390 ↗
2. 10.1016/S2214-109X(14)70361-410.1016/S2214-109X(14)70361-4 ↗
3. 10.1056/NEJMoa130365710.1056/NEJMoa1303657 ↗
4. 10.1016/S0140-6736(06)68507-310.1016/S0140-6736(06)68507-3 ↗
5. 10.1371/journal.pone.007274510.1371/journal.pone.0072745 ↗
6. 10.1586/erv.09.16010.1586/erv.09.160 ↗
7. 10.1016/j.ejpb.2010.09.00810.1016/j.ejpb.2010.09.008 ↗
8. 10.1016/S1471-4906(01)01865-810.1016/S1471-4906(01)01865-8 ↗
9. 10.1016/j.micres.2006.11.01610.1016/j.micres.2006.11.016 ↗
10. 10.1186/1471-2180-11-16710.1186/1471-2180-11-167 ↗
11. 10.1002/eji.20042509010.1002/eji.200425090 ↗
12. 10.1371/journal.pone.007568410.1371/journal.pone.0075684 ↗
13. 10.4049/jimmunol.181.11.794810.4049/jimmunol.181.11.7948 ↗
14. 10.1016/j.drudis.2009.02.00910.1016/j.drudis.2009.02.009 ↗
15. 10.1128/IAI.72.3.1608-1617.200410.1128/IAI.72.3.1608-1617.2004 ↗
16. Verma I Pandey R Khuller G. Liposomes as adjuvant for anti-mycobacterial vaccine development. 2004;42(10):949-954.
17. 10.1016/0005-2736(86)90479-710.1016/0005-2736(86)90479-7 ↗
18. 10.1016/j.tube.2003.08.01010.1016/j.tube.2003.08.010 ↗
19. 10.1016/S0966-842X(02)02344-210.1016/S0966-842X(02)02344-2 ↗
20. 10.1016/j.tube.2004.09.01110.1016/j.tube.2004.09.011 ↗
21. 10.1016/0923-2494(92)80060-X10.1016/0923-2494(92)80060-X ↗
22. 10.4049/jimmunol.090401310.4049/jimmunol.0904013 ↗
23. 10.1371/journal.pone.000311610.1371/journal.pone.0003116 ↗
24. 10.1084/jem.2008144510.1084/jem.20081445 ↗
25. Amini Y, Tafaghodi M, Amel Jamehdar S, et al. Heterologous expression, purification, and characterization of the HspX, Ppe44, and EsxV proteins of Mycobacterium tuberculosis. Rep Biochem Molecular Biol. 2018;6:125–130.
26. 10.1016/S0009-3084(00)00127-410.1016/S0009-3084(00)00127-4 ↗
27. Hojatizade M, Badiee A, Khamesipour A, et al. DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice. Nanomed J. 2017;4:71–82.
28. 10.1038/nrmicro121110.1038/nrmicro1211 ↗
29. 10.1007/s00253-015-6962-x10.1007/s00253-015-6962-x ↗
30. 10.1371/journal.pone.013064110.1371/journal.pone.0130641 ↗
31. 10.1073/pnas.131497311110.1073/pnas.1314973111 ↗
32. 10.1016/j.vaccine.2008.09.02510.1016/j.vaccine.2008.09.025 ↗
33. 10.1111/pbi.1218510.1111/pbi.12185 ↗
34. Yousef Amini MT, Saeid AJ, Zahra M, et al. Heterologous expression, purification, and characterization of the HspX, Ppe44, and EsxV proteins of Mycobacterium tuberculosis. Rep Biochem Molecular Biol. 2017;6(2):125-130.
35. 10.1016/0167-5699(90)90034-710.1016/0167-5699(90)90034-7 ↗
36. Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Brazilian J Med Biol Res. 1999;32(2):181-189.10.1590/S0100-879X1999000200006 ↗
37. 10.1016/j.vaccine.2007.05.00910.1016/j.vaccine.2007.05.009 ↗
38. 10.1128/CVI.00413-0710.1128/CVI.00413-07 ↗
39. 10.1016/j.vaccine.2017.01.07910.1016/j.vaccine.2017.01.079 ↗
40. 10.1016/j.bbamem.2005.10.01110.1016/j.bbamem.2005.10.011 ↗
41. 10.1055/s-1997-135810.1055/s-1997-1358 ↗
42. 10.1016/j.actatropica.2013.07.02110.1016/j.actatropica.2013.07.021 ↗
43. 10.1016/j.jconrel.2011.05.01910.1016/j.jconrel.2011.05.019 ↗
44. 10.1021/mp400372j10.1021/mp400372j ↗
45. 10.1007/s10875-007-9084-010.1007/s10875-007-9084-0 ↗
46. 10.1002/eji.20032395610.1002/eji.200323956 ↗
47. 10.4049/jimmunol.175.2.78810.4049/jimmunol.175.2.788 ↗
48. 10.4049/jimmunol.090333210.4049/jimmunol.0903332 ↗
49. 10.1126/science.126066810.1126/science.1260668 ↗
50. 10.1038/ni144910.1038/ni1449 ↗
51. 10.1016/j.it.2004.06.00510.1016/j.it.2004.06.005 ↗
52. 10.4049/jimmunol.172.11.693810.4049/jimmunol.172.11.6938 ↗
53. 10.1086/42253210.1086/422532 ↗
54. 10.1371/journal.ppat.100390510.1371/journal.ppat.1003905 ↗
55. 10.1016/j.tube.2016.08.00110.1016/j.tube.2016.08.001 ↗
56. 10.1128/IAI.72.11.6622-6632.200410.1128/IAI.72.11.6622-6632.2004 ↗
57. 10.4049/jimmunol.171.3.160210.4049/jimmunol.171.3.1602 ↗